Demand for Biological Implants and Impact of COVID-19……..
Global biological
implant market is anticipated
to reach USD 9.8 billion by 2024,
according to a new report by Grand View Research, Inc. Biological implant
market is driven by rise in adoption of grafts and organ substitutes for
reconstructive surgeries for various clinical applications such as
cardiovascular, orthopedic and other soft tissue repair. The main challenge
associated with the use of these products is to incorporate such a material
that can specifically adapt to the biology of the surrounding environment in
order to accelerate regeneration and repair. To overcome this challenge,
research endeavors are carried out in order to develop such devices from
biological source thus affecting industrial growth in the coming years.
Multiple therapeutic regimens are being
followed across the globe in attempts to come up with a reliable treatment for
Covid-19. One line of treatment includes the use of hydroxychloroquine, while a
second treatment line focuses to use antiviral drugs used in the disease
management of HIV. Both these approaches have surged demand from advanced antivirals
and antimalarial drugs. This impacts the drug manufacturers as an off label
indication for these drug classes has to be worked upon. At the moment, the WHO
has not prescribed any of these approaches, neither they have commented if one
is better than the other. The report will account for Covid19 as a key market
contributor.
Modification in the process of
composite grafting is expected to play a crucial role in tackling
reimplantation of amputated fingertips by bringing development in the overall process
of grafting. Moreover, rising competition amongst key participants operating in
this market is one of the high impact rendering factors to accelerate the
growth.
"Biological implants market is driven by
development in composite grafting coupled with rising advancements in tissue
engineering"
The global biological implants market
was valued at USD 5,070.8 million in 2015 and is expected to exhibit a growth
rate of 7.6% over the forecast period. With technological breakthroughs in the
fields of regenerative medicine and tissue engineering, the market for
biological implants is expected to witness substantial demand and sales over
the forecast period.
Emergence of biomaterials to perform
reconstructive procedures that are compatible and less cumbersome will
considerably increase the revenue generation and drive progress up to 2024.
Substantial advancements have been made in precise implant surgical procedures
for more aesthetic and predictable outcomes. Aforementioned developments and
advancements in implant and tissue regeneration collectively bolsters growth
for these products.
To Request Sample Copy of this report, click the link:
Further key findings from the report suggest:
·
Depending upon the source or
donor of grafts, products offered can be categorized into autograft,
allografts, and xenografts. Xenografts dominated the revenue share in 2015 with
a revenue share of over 50%. However, allografts are expected to witness the
fastest growth owing to the fact that they are derived from same species and
produce considerably less chances of foreign immune reaction, thereby
influencing adoption rate.
·
Biological implants serve
various application domains which include cardiovascular, orthopedic, and other
soft tissue implants. Soft tissue products accounted for the largest share in
2015 as a result of higher usage of the products in the field of dentistry.
Even though cardiovascular implants accounted for lowest penetration in the
current scenario, demand for cardiovascular stents and valves obtained from
biological source is expected to expand, consequently boosting revenue
generation from this segment.
·
Amongst surgical and injectable
mode of administration, surgical mode is estimated to hold the larger share, as
a consequence of availability of several products administered via this route.
Introduction of minimally invasive techniques for surgical incorporation of
grafts is also one of the significant factors propelling growth in this
segment.
·
North America dominated the
market with a revenue share of 50% due to widespread presence of participants
coupled with high aesthetic and healthcare awareness levels amongst the
population in this region.
·
Asia Pacific is estimated to
exhibit the fastest growth in the coming years due to presence of the target
population and rapidly improving health care infrastructure which is attributed
to drive the demand for tissue engineered products and biological implants.
·
Major players operating in this
industry include Medtronic, NuVasive, Inc, Stryker Corporation, Conmed
Corporation, CryoLife, Edwards LifeSciences Corporation, Acelity, Integra
LifeSciences Corporation, Allergan Plc, RTI Surgical, IOP Ophthalmics,
Organogenesis Inc, BioPolymer GmbH & Co. KG, Osiris Therapeutics, Baxter
International, Vericel, Aplhatec Spine Inc, Maxigen Biotech Inc, Auto Tissue
Berlin GmbH, MiMedx Group, Inc., Biotissue Technologies,
·
These players are undertaking
different business strategies to boost their respective penetration and enhance
market presence. These strategies include novel product developments and
geographic expansion by involving in collaborative activities in order to grab
the larger share of revenue. For instance, in April 2016, Stryker Corporation
acquired Stanmore Implants Worldwide Limited which is expected to enable the
company to provide differentiated technologies to orthopedic oncology surgeons,
thus propelling growth over the forecast period.
Moreover,
companies are playing pivotal role in addressing the challenge of foreign body
rejection associated with synthetic devices by development of biologically
derived reconstructive solutions. Novel product development will continue to
rise globally, encouraging companies to proactively optimize their portfolios
in this vertical, consequently influencing revenue generation.
Development
in the regenerative medicine sector which includes a variety of therapeutic
approaches such as utilization of bio based materials and biologics for
targeting the root cause of an ailment has sparked a new trend leading to
increasing adoption of these products is one of the crucial factors propelling
market growth over the forecast period. Development of soft tissue grafts for a
number of complex procedures such as abdominal wall reconstruction, thoracic
reconstruction, breast reconstruction among others owing to lower contamination
rates of bioprosthetic mesh materials along with stable vascularization even at
infected wound sites and lower visceral repair site adhesions are key reasons
due to which they are used as compared to prosthetic mesh materials.
High
manufacturing cost and hesitant uptake due to adverse events are anticipated to
derail the projected progress to a certain extent.
“Xenografts
accounted for the largest share of the product segment in 2015"
Xenografts
accounted for the largest share in 2015 owing to advancements in the field of
vascular engineering and tissue engineering for the treatment of diseases with
the use of scaffold that is a structurally intact xenogeneic vessel, such as a
pig aorta. Availability and ease of procurement of the xenogeneic grafts
without the issue of donor site morbidity is anticipated to impact revenue
generation significantly.
Allografts
are expected to experience the fastest growth in the coming years. Superior
aesthetic results obtained with their use is anticipated to augment the sale
and demand in this segment.
Have any Query? Ask our Experts:
"Rising incidence of cardiovascular
disorders are expected to propel the cardiovascular implants segment
growth"
Various
applications of these products includes orthopedic, cardiovascular and other
soft tissue implants. Soft tissue implants held the majority share of over 44%
owing to the availability of wide range of products falling in this category.
Although,
cardiovascular implants are observed to have low penetration in 2015, it is
expected to witness fastest growth in the coming years. Rising incidence of
cholesterol abnormalities and cardiovascular disorders is anticipated to
positively reinforce this segment’s potential in the coming years. Availability
of various cardiac tissues in the market in the form of allograft valves,
heterograft valves that are obtained from porcine heart & bovine
pericardial valves, and a stentless valve which can be trimmed according to the
requirement is attributed to the projected progress in this segment.
"Surgical biological implants are most
adopted route of administration"
Grand View Research has segmented
biological implant market on the basis of product, application, mode of
administration:
Devices Outlook, by Product (Revenue, USD Million, 2013 -
2024)
·
Autografts
·
Allografts
·
Xenografts
Outlook, by Application (Revenue, USD Million, 2013 -
2024)
·
Cardiovascular Implants
·
Orthopedic Implants
·
Other Soft Tissue Implants
Devices Outlook, by Mode of Administration (Revenue, USD
Million, 2013 - 2024)
·
Surgical
·
Injectable
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment